Faculty, Staff and Student Publications
Publication Date
6-1-2007
Journal
Molecular Microbiology
Abstract
Linezolid, which targets the ribosome, is a new synthetic antibiotic that is used for treatment of infections caused by Gram-positive pathogens. Clinical resistance to linezolid, so far, has been developing only slowly and has involved exclusively target site mutations. We have discovered that linezolid resistance in a methicillin-resistant Staphylococcus aureus hospital strain from Colombia is determined by the presence of the cfr gene whose product, Cfr methyltransferase, modifies adenosine at position 2503 in 23S rRNA in the large ribosomal subunit. The molecular model of the linezolid-ribosome complex reveals localization of A2503 within the drug binding site. The natural function of cfr likely involves protection against natural antibiotics whose site of action overlaps that of linezolid. In the chromosome of the clinical strain, cfr is linked to ermB, a gene responsible for dimethylation of A2058 in 23S rRNA. Coexpression of these two genes confers resistance to all the clinically relevant antibiotics that target the large ribosomal subunit. The association of the ermB/cfr operon with transposon and plasmid genetic elements indicates its possible mobile nature. This is the first example of clinical resistance to the synthetic drug linezolid which involves a natural resistance gene with the capability of disseminating among Gram-positive pathogenic strains.
Keywords
Acetamides, Anti-Bacterial Agents, Bacterial Proteins, DNA Transposable Elements, Drug Resistance, Bacterial, Humans, Methicillin Resistance, Methyltransferases, Microbial Sensitivity Tests, Molecular Sequence Data, Operon, Oxazolidinones, Plasmids, Protein Synthesis Inhibitors, RNA, Ribosomal, 23S, Sequence Analysis, DNA, Staphylococcus aureus